Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 October, 2018 20:21 IST
Cadila Healthcare's JV facility of Zydus Hopsira Oncology receives EIR from USFDA
Source: IRIS | 12 Jul, 2018, 01.23PM
Comments  |  Post Comment

Cadila Healthcare announced that the manufacturing facility of Zydus Hopsira Oncology, a 50:50 joint venture company between Zydus Cadila and Hospira Inc., USA (now part of Pfizer Group) at Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA which concluded that the inspection is "closed" and states that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI). The manufacturing plant had completed the USFDA audit from April 5 to 12, 2018.

Shares of the company declined Rs 3, or 0.81%, to trade at Rs 368.50. The total volume of shares traded was 107,976 at the BSE (1.09 p.m., Thursday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Biocon, Mylan announce positive CHMP Opinion for Ogivri - 22-Oct-2018 10:28
Lupin announces positive CHMP opinion for NaMuscla - 22-Oct-2018 09:51
Tejas Networks bags Rs 1.11 bn order from Sterlite Technologies - 22-Oct-2018 09:45
Alembic Pharma' JV completes USFDA inspection of Karakhadi unit - 22-Oct-2018 09:41
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer